奥美拉唑
兰索拉唑
雷贝拉唑
泮托拉唑
质子抑制剂泵
安慰剂
胶囊
医学
药理学
加药
胃酸
化学
胃肠病学
内科学
胃
替代医学
病理
生物
植物
作者
D. Pantoflickova,Gian Dorta,M. Ravic,Philippe Jornod,A. L. Blum
标识
DOI:10.1046/j.1365-2036.2003.01496.x
摘要
Summary Background: Rapid and consistent acid suppression on the first day of dosing may be important in treating acid‐related disorders. Aim: To compare the antisecretory activity and onset of action of single doses of rabeprazole, lansoprazole, pantoprazole, omeprazole capsule, omeprazole multiple unit pellet system (MUPS) tablet and placebo in healthy Helicobacter pylori ‐negative subjects. Methods: This cross‐over, double‐blind, randomized study was performed in 18 H. pylori ‐negative subjects. Twenty‐four‐hour intragastric pH monitoring was performed on the day of treatment (once‐daily dose of rabeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, omeprazole capsule 20 mg, omeprazole MUPS tablet 20 mg or placebo). Results: The intragastric pH (3.4) and time at pH > 4 during the 24 h post‐dose (8.0 h) were significantly greater with rabeprazole than with lansoprazole, pantoprazole, omeprazole capsule, omeprazole MUPS tablet or placebo ( P ≤ 0.04 for rabeprazole vs. the others). Daytime and night‐time pH values were higher with rabeprazole and lansoprazole than with pantoprazole, omeprazole capsule and omeprazole MUPS tablet ( P ≤ 0.04). Conclusion: Rabeprazole was the most potent acid inhibitor of all the proton pump inhibitors tested during the first day of dosing.
科研通智能强力驱动
Strongly Powered by AbleSci AI